R&D partnering vision
Our vision is to drive innovation through healthy and productive alliances. We have the skills and experience within drug and device development to turn your ideas into treatment solutions for patients. We leverage our protein expertise to develop life-changing treatments for people living with chronic diseases.Download our partnering for innovation brochure
Novo Nordisk has been a leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition. We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention.
Our ambition is to change possibilities for people with haemophilia. Every step of our journey is focused on improving treatment options, providing better access to care and following through on our commitment to understand the needs of people with haemophilia.
Autoimmune inflammatory disorders
Our ambition is to develop novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, lupus, inflammatory bowel disease, and psoriatic arthritis. We have a number of innovative monoclonal antibody projects in early clinical development.
Novo Nordisk has been a major player in the field of growth hormone therapy for many decades. We keep exploring new modalities to treat human growth hormone disorders.
In 1985, Novo Nordisk introduced the world’s first insulin pen. Since then, we have made extensive efforts in R&D of new delivery systems to help people with chronic diseases manage their treatment.Our partnering focus within protein delivery
Meet us at partnering events around the world
We attend international events throughout the year to meet with new potential partners.